UBS Group
IPCI

UBS Group’s Intellipharmaceuticals International Inc. IPCI Stock Holding History

UBS Group’s Portfolio IPCI Stock Details IPCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-2,339
Closed -$10K – 8500
2018
Q2 		$10K Buy
+2,339
New +$10.6K ﹤0.01% 7168
2018
Q1 		– Sell
-862
Closed -$7K – 8414
2017
Q4 		$7K Buy
+862
New +$7.83K ﹤0.01% 7272
2017
Q2 		– Sell
-202
Closed -$5K – 8221
2017
Q1 		$5K Sell
202
-483
-71% -$12.4K ﹤0.01% 7029
2016
Q4 		$19K Buy
+685
New +$19.1K ﹤0.01% 6558
2015
Q4 		– Sell
-74
Closed -$1K – 8721
2015
Q3 		$1K Buy
+74
New +$1.95K ﹤0.01% 8279
2015
Q1 		– Sell
-10
Closed – – 9713
2014
Q4 		$0 Buy
+10
New +$270 ﹤0.01% 9701

Other funds holding IPCI

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
FANJ
Financial Architects (New Jersey) Marlton, New Jersey $663M AUM 15.53% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return

UBS Group's IPCI Position: Q3 2018 in Review

UBS Group sold out of Intellipharmaceuticals International Inc. (IPCI) in Q3 2018, closing a stake of 2,339 shares — an estimated $10K sold.

UBS Group first reported a position in IPCI in Q4 2014 and held it in 6 quarters. The position peaked at $19K in Q4 2016. 10 funds tracked by Wall St. Rank hold IPCI as of Q3 2018.

  • UBS Group reported no remaining Intellipharmaceuticals International Inc. position as of Q3 2018 after selling out during the quarter.
  • UBS Group sold 2,339 Intellipharmaceuticals International Inc. shares in Q3 2018, an estimated $10K.
  • UBS Group first reported a position in Intellipharmaceuticals International Inc. in Q4 2014 and held it in 6 quarters.
  • UBS Group's Intellipharmaceuticals International Inc. position peaked at $19K in Q4 2016.
  • 10 funds tracked by Wall St. Rank held Intellipharmaceuticals International Inc. as of Q3 2018.

Based on UBS Group's 13F filing for Q3 2018, filed 14 Nov 2018.